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Diacylglycerol kinase (DGK) is a lipid kinase converting diacylglycerol to phosphatidic acid, and regulates many
enzymes including protein kinase C, phosphatidylinositol 4-phosphate 5-kinase, and mTOR. To date, ten mammalian
DGK subtypes have been cloned and divided into five groups, and they show subtype-specific tissue distribution.
Therefore, each DGK subtype is thought to be involved in respective cellular responses by regulating balance of the
two lipid messengers, diacylglycerol and phosphatidic acid. Indeed, the recent researches using DGK knockout mice
have clearly demonstrated the importance of DGK in the immune system and its pathophysiological roles in heart
and insulin resistance in diabetes. Especially, most subtypes show high expression in brain with subtype specific
regional distribution, suggesting that each subtype has important and unique functions in brain. Recently, neuronal
functions of some DGK subtypes have accumulated. Here, we introduce DGKs with their structural motifs,
summarize the enzymatic properties and neuronal functions, and discuss the possibility of DGKs as a therapeutic
target of the neuronal diseases.Introduction
Diacylglycerol kinase (DGK) is the enzyme which phos-
phorylates diacylglycerol (DG) resulting in the produc-
tion of phosphatidic acid (PA) [1-5]. Both DG and PA
are very important signaling molecules. DG regulates
the activity and localization of several proteins, including
protein kinase C (PKC), chimerins, Unc-13, and Ras
guanyl nucleotide-releasing protein (RasGRP). PA also
activates several enzymes, including phosphatidylinositol
4-phosphate 5-kinase, mammalian target of rapamycin
(mTOR), and atypical isoforms of PKC [6-10]. Therefore,
DGK is thought to be a key enzyme that regulates nu-
merous cellular responses by regulating balance of the
two lipid messengers.
So far, ten mammalian subtypes of DGK have been
cloned [11-20] and categorized into five groups depending
on their structural motifs (Figure 1). All DGKs have two
cysteine-rich regions (C1A and C1B domains), except for
DGKθ which has three regions, in the regulatory domain
of the N-terminal half of the molecule. These C1 domains
of DGKs are homologous to those of PKC, which shows a* Correspondence: shirai@kobe-u.ac.jp
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unless otherwise stated.DG-dependent protein kinase activity. However, not all of
the C1 domains but only those of DGKβ and γ show the
binding activity to DG [21]. All DGKs have a catalytic do-
main in the C-terminal half of the molecule, and the cata-
lytic domain of Type II DGKs (δ, η, and κ) is separated
into two portions by an insertion. In addition to these do-
mains, they have different structures depending on their
groups. Type I DGKs, DGKα, β, and γ, have a recoverin
homology (RVH) domain and an EF-hand motif. The
RVH and EF-hand motif domains are thought to be a
calcium ion sensor as described below. Type II DGKs,
DGKδ, η, and κ have a pleckstrin homology (PH) domain
at N-terminus and have sterile alpha motif (SAM) domain
at C-terminus. Type III DGK, DGKε, has only the C1 do-
mains. Type IV DGKs, DGK ζ and ι, have a myristoylated
alanine rich protein kinase C substrate phosphorylation
site like region (MARCKS homology domain) between the
C1 and catalytic domains, four ankyrin repeats, and a PDZ
binding site at C-terminus. Finally, Type V DGK, DGKθ
has a proline and glycine rich domain as well as a PH do-
main overlapping with a Ras associating domain. In
addition, many splice variants are reported [3,5].
Each subtype of DGK shows a subtype-specific tissue
expression pattern (Table 1). For example, DGKβ, γ, ε, ζ, ι,
and θ are localized in neurons and DGKα is reported to
be localized in oligodendrocytes, although most DGKs areral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Schematic illustration of DGKs with the phosphorylation sites. RVH; recoverin homology domain; PH; pleckstrin homology, SAM;
sterile alpha motif, MARCKS; myristoylated alanine rich protein kinase C substrate phosphorylation site. Numbers and alphabets show the
phosphorylation sites reported.
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is expressed in caudate putamen, hippocampus, and cere-
bral cortex but not in cerebellum [12]. Instead, cerebellum
expresses DGKγ, θ, and ζ. In addition, DGKα is highly
enriched in immunological organs such as spleen and thy-
mus. DGKζ is highly expressed in thymus and brain, with
substantial levels in skeletal muscle, heart, and pancreas
[16,23]. DGKδ shows ubiquitous expression includingTable 1 Characteristics of mammalian DGK subtypes
MW(KDa) Localization Enzymatic prope
α 80 thymus, spleen> > kidny,
brain (oligodendrocytes)
Ca2+, PS dependent
sensitive activated by PIP
β 90 brain(CP > hip, cortex, olf) >
adrenal gland > small intestine
Ca2+, PS dependent a
by PI(4,5)P2




δ 130 skeletal muscle > testis, colon Ca2+, PS independ
η 130-140 testis > brain, lung, spleen > heart Ca2+ insensitiv
κ 142 testis > spleen, pracenta, Ca2+ insensitiv
ε 64 retina,brain,testis > ovary> >
skeletal muscle heart
Ca2 + independent se
for arachidonoyl
ζ 104 thymus > brain(Cb, hip, olf)> >
skeltal muscle, heart, pancreas
Ca2 + insensitive M
PS dependent
ι 130 retina > brain
(hip, CP, cortex, Cb, Dg)
Ca2+ insensitiv
θ 110 brain(Cb, hip)> >
small intestine, liver etc.
Ca2+ insensitiv
Cb; cerebellum, CP: caudate putamen, Dg; dandate gyrus, hip; hippocampus, Olf; olskeletal muscle and testis [15,24]. The different expression
patterns suggest a subtype-specific function of DGKs. In-
deed, DGKα and ζ knockout (KO) mice demonstrate their
importance in the immune system [25,26] and DGKζ ΚΟ
mice reveal its important role in cardiac hypertrophy [27].
Moreover, DGKδ plays a key role in insulin resistance in
diabetes [28]. However, in spite of the abundant expres-
sion of DGKs in brain, their neuronal functions had beenrty Function/Phenotype of KO References
R59022
3, PI(3,4)P2
T cell anergy tumor invasion
insulin release
[11,25,33-37]
ctivated impairment of memory impairment of





ent type II diabetes EGF signaling, seizure [15,24,28,40,41]







g2+, T cell anergy, cell cycle control
spine maintenamce
[17,26,27,33,35,47,48]
e Ras GRP, Rap 1 signaling [19,22,49,50]
e neurotransmitter release? [18]
factory bulb.
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have reported the importance of DGKs in brain functions
[22,29-32]. In the following sections, we summarize the
enzymatic properties and neuronal functions of DGKs for
the development of drugs targeting the neuronal diseases.
Review
Regulation of the enzymatic activity
Although the enzymatic characteristics of all DGK sub-
types have not been investigated, the activities of some
DGKs are regulated by ionic detergents and phospho-
lipids [33,34]. For example, the activities of DGKα and ζ
depend on deoxycholate or cholic acid, so that a deter-
gent, octyl glucoside, is used for the DGK assay. But the
dependency of phospholipids seems to be subtype spe-
cific (Table 1). The activity of purified DGKα is remark-
ably enhanced by phosphatidylcholine (PC) but not by
phosphatidylinositol (PI), while DGKζ is activated by PI
and phosphatidylserine (PS), but not so remarkably
by PC [33]. DGKα is activated by PI3,4,5-trisphosphate
(PIP3) and PI3,4-bisphosphate [PI(3,4)P2], while DGKβ
is activated by PI4,5-bisphosphate [PI(4,5)P2] [34]. More-
over, divalent cations including calcium and magnesium
are also required for activation of DGKα and ζ [35,51].
Specifically, Type I DGKs are believed to depend on cal-
cium because they have the EF hand motif and RVH do-
mains. The calcium dependency of DGKα has been clearly
shown in vitro [35]. In addition to its role as a calcium
sensor, the N-terminus region has an inhibitory effect on
the kinase activity [52,53]. Indeed, the N-terminus region
binds to its C-terminal region containing the kinase do-
main and C1 domain in the absence of calcium [54]. How-
ever, the in vitro calcium-dependent activity of DGKβ and
γ has not been reported, although their EF-hands seem to
bind to calcium and to regulate their kinase activity as
well. Information of the enzymatic properties of each
DGK subtype is not enough, and the precise enzymatic
characterization should be carried out using the purified
proteins under the respective optimized conditions.
All DGKs except for DGKβ are localized in cytoplasm in
several cells, but some DGKs show the translocation to
the plasma membrane and/or intracellular organelles in
response to several stimulations [35,55-61]. For example,
DGKγ is translocated from the cytoplasm to the plasma
membrane by calcium, phorbol ester, and purinergic re-
ceptor stimulations [55]. DGKα is also translocated to the
plasma membrane by calcium [35], purinergic receptor
stimulation [55], and T-cell receptor stimulation [56].
Moreover, DGKδ translocates to the plasma membrane in
response to phorbol ester [57]. These are coincident with
the fact that DG is produced on the plasma membrane
and DGKs work there. In addition to the plasma mem-
brane, DGKα is accumulated at the Golgi complex in the
case of arachidonic acid and vitamin E stimulations[55,58]. Furthermore, it is reported that DGKζ is translo-
cated from the nucleus to the cytoplasm [59], and DGKθ
and γ are localized in the nucleus [60,61], consistent with
the fluctuation of DG and PA contents in the nucleus
[62-64]. These findings indicate that translocation is the
key regulation mechanism to define where and how long
each DGK works, and suggest that DGKs are important for
the DG/PA metabolism in the plasma membrane and many
organelles including nucleus and Golgi complex. In the case
of DGKβ, the plasma membrane localization seems to be a
critical for its physiological function [29].
The translocation and activation of some DGKs are regu-
lated by the phosphorylation reaction. We have revealed
that DGKγ is subtype-specifically phosphorylated by PKCγ
at Ser-776 and Ser-779 upon the purinergic stimulation,
resulting in up-regulation of its lipid kinase activity [65].
The membrane translocation of DGKδ is regulated by the
phosphorylation at Ser-22 and Ser-26 by conventional/clas-
sical PKC (cPKC) [66], and the nuclear export of DGKζ is
dependent on the phosphorylation at the MARCKS hom-
ology domain by PKCα [67]. Not only the serine phosphor-
ylation but also the tyrosine phosphorylation is important:
the membrane translocation of DGKα is dependent on
phosphorylation at Tyr-334 (Tyr-335 in mouse) by Src
family tyrosine kinases [58,68,69]. We also found that Tyr-
218 of DGKα is phosphorylated by c-Abl tyrosine kinase
and the phosphorylation regulates serum-induced nuclear
export of the enzyme [70]. These results indicate that the
phosphorylation is one of the important regulation mecha-
nisms for the spatial regulation of diacylglycerol signaling.
DGK and brain function related to neuronal disease
DGKβ and η in mood disorder and memory loss
Most subtypes of DGKs are abundant in brain (Table 1 and
Ref. 22). Above all, high levels mRNA of DGK β, γ, ζ, ι, and
θ are detected in the neurons. In situ hybridization reveals
that DGKβ is expressed in the caudate putamen, accum-
bens nucleus, and hippocampus [12]. Indeed, the protein
expression of DGKβ in these regions is reported [29,38].
DGKβ is not present at the birth but its expression is rap-
idly increased from day 14 to day 28, and is localized on
the plasma membrane of spines [38], suggesting its import-
ance in the neuronal network. Indeed, Goto et al. have re-
ported that DGKβ is expressed at post synaptic sites in
medium spiny neurons constituting the striatonigral and
striatopallidal pathways [39,71].
To investigate the neuronal functions of DGKβ, we pro-
duced its KO mice and found that the primary cultured
hippocampal neurons from DGKβ KO mice had less
branches and spines compared to the wild type. In
addition, long-term potentiation in the hippocampal CA1
region of the DGKβ KO mice was reduced, causing im-
pairment of cognitive functions including spatial and
long-term memories in Y-maze and Morris water-maze
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of emotion [30]: DGKβ KO mice spent longer time in the
center area in the open field test, and in the open arms in
elevated plus maze test than the wild type. On the other
hand, DGKβ KO mice showed normal input–output rela-
tionship and behavior in prepulse inhibition test and social
interaction test [29,31]. These results suggest that DGKβ
KO mice have a mania-like behavior with memory loss, al-
though their social skill and basal synaptic function are
normal. The importance of DGKβ in the memory and
emotion fits to the localization of DGKβ in hippocampus
and caudate putamen, and its developmental changes [38].
Interestingly, the impairment of emotion and memory of
DGKβ KO mice is rescued with the lithium treatment for
ten days ([30], and unpublished data). The effect of lithium
seems to involve in GSK3β inhibition [30]. These results
suggest that DGKβ can be a possible target of memory loss
and mood disorder. Indeed, DGKβ is reported as one of the
learning-regulated genes in a research of age-dependent
memory impairment [72]. This report indicates that histone
acetylation is associated with age-dependent memory im-
pairment and histone deacetylase inhibitor is expected as a
drug for memory loss [73]. Moreover, one of the splice vari-
ant forms of human DGKβ, which lacks 35 amino acids at
the C-terminus but has an additional 4-amino-acid exten-
sion (DGKβ SV3; GenBank accession number AX032745),
is associated with a human DGKβ EST that is annotated as
differentially expressed in patients with mood disorders
[74]. The splice variant form does not induce branches and
spines [29], supporting the important role of DGKβ in
spine formation.
Similarly, a mutation in DGKη is reported to correlate
with bipolar disorder [42-44], of which mRNA seems to
be concentrated in hipocaumpus and dendate gyrus, al-
though the expression level of the subtype in the brain is
lower than in testis and tumor-derived cells [45]. Baum
et al. have reported strong association between bipolar dis-
order and SNPs located in a gene encoding DGKη by the
genome-wide association study using the samples from
European origin [42], and an increase in its mRNA level
has been reported in some patients with bipolar disorder
and schizophrenia [43,44], On the other hand, other stud-
ies have not confirmed the association [75-77]. The con-
troversial results may be due to the races and methods
employed. The precise experimental procedures would be
necessary to prove the involvement of DGKη in bipolar
disorder.
DGKζ and ι in spine modulation and neurotransmitter release
DGKζ, which is abundant in cerebellum, hippocampus,
and olfactory bulb, is involved in spine maintenance
[47,78]. For this function, its enzymatic activity and
localization at the excitatory postsynaptic site by binding
to some PSD95 family proteins through the PDZ-binding domain are critical. Interestingly, DGKζ is de-
tected in the nucleus in the hippocampal neurons but it
is translocated to the cytoplasm by ischemia or kainate
stimulation [79,80], suggesting its role in the protection
against ischemia. The subtype is also expected to be in-
volved in the leptin receptor signaling because it associates
with leptin [81]. However, detailed mechanisms are still
unclear. DGKι also has the PDZ binding motif. The sub-
type is abundantly detected in hippocampus, dendate
gyrus, and retina with moderate levels in the cortex,
caudate-putamen, and thalamus [19,22,82]. However, the
spine density and morphology of neurons in DGKι ΚΟ are
normal [49]. Instead, DGKι regulates the presynaptic re-
lease during metabotropic glutamate receptor-dependent
long-term potentiation [32,49]. Abnormal behaviors in-
cluding impairment of memory and emotion of DGKζ and
ι KO mice have not been reported yet.
DGKβ, ε, and δ in seizure
Seizure is a relatively common neuronal disease and at
least three DGK subtypes are related to the disease. DGKε
is uniformly expressed in brain, and its KO mice show an
increased resistance to electroconvulsive and faster recov-
ery than the wild type [46]. DGKδ is also associated to
seizure, although its neuronal expression is very low:
DGKδ gene is disrupted in a female patient with a de novo
balanced translocation, who exhibits seizure with several
dysfunctions, and electroencephalographic assessment of
DGKδ mutant mice revealed abnormal epileptic dis-
charges and electrographc seizures [40]. In addition, we
also showed that seizure is severer in DGKβ KO mice than
the wild type [31].
Other DGKs
DGKα is detected in oligodentrocytes, although the sub-
type is not enriched in brain [11,83]. DGKγ, which is pre-
dominantly localized in Purkinje cells and hippocampus,
is present at birth and then gradually increased [13,38].
The mRNA expression of DGKθ is the highest in cerebel-
lum and hippocampus [18] and it is suggested that DGKθ
is involved in neurotransmitter release [84]. However, fur-
ther examination would be necessary to understand
physiological functions of DGKα, γ, and θ in brain.
Perspective
As described above, some DGKs are important for neur-
onal functions. This is supported by their abundant and
subtype-specific expression in brain. Generally, DGKs are
likely involved in the spine formation and maintenance,
contributing to higher brain function including memory
and emotion. However, the detailed mechanisms of the
DGK-mediated morphological change of spines and neu-
rons are not clear. The membrane lipids including PA and
DG seem to be the key molecules. Indeed, we found that
Figure 2 A schema of functions of DGKs in brain. DGKβ regulates spine formation and branching, contributing to higher brain functions
including memory and emotion. DGKζ and ι are involved in spine maintenance and neurotransmitter modulation, respectively. DGKε and δ are
reported to be related to mood disorder. DGKη seems to be correlated to seizure. The control of membrane DG and PA is a key step, and
protein-protein interaction like DGKζ and PSD95 is critical for the functions of DGKs.
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respectively, are involved in the DGKβ-induced neurite in-
duction and branching [unpublished data], and the kinase
activity is necessary for the DGKζ-mediated spine main-
tenance [22,47]. Alternatively, PIP2 and/or PIP3 may be
additional key lipids because some DGKs can be activated
by these inositol phospholipids, which are related to
actin cytoskeletal rearrangement and membrane traffic
[85]. On the other hand, unknown mechanism like a
kinase-independent pathway may additionally exist. For
example, we have recently found that there is a kinase-
independent pathway in the DGKβ-induced neurite induc-
tion and branching [86]. Further investigations are neces-
sary to reveal the whole story regulating the shape of the
neuronal membrane by DGKs.
The facts described in this review suggest that some
DGKs can be a target for the therapy of neuronal diseases
including memory loss, mood disorder, and seizure. To
develop the drugs targeting DGKs for these neuronal dis-
eases, more precise experiments should be performed
using human patients. For example, there is still no evi-
dence that splice variant forms of DGKβ is expressed at
protein level in human patients of bipolar disorder, al-
though it is suggested to association with mood disorders
[74]. More importantly, it is necessary to find subtype-
specific inhibitor and/or activator of each DGK subtype be-
cause DGKs have subtype-specific and numerous physio-
logical functions as summarized in Table 1. Recently,
Sakane et al. have developed a new DGK assay method
suitable for the high throughput screening [87]. Sakane’s
and our groups are collaborating to find specific inhibitor
and/or activator of each DGK subtype. In near future, it
will be possible to provide information about DGK-subtype
specific inhibitor and/or activator which would be usefulfor the development of drugs targeting DGK for neuronal
diseases.
DGKs are involved in not only neuronal diseases but also
other diseases including diabetes, immuno-dysfunctions,
and cardiovascular diseases. In addition, the correlation be-
tween cancer and DGK has been recently reported. For ex-
ample, DGKα is involved in the progression of human
hepatocellular carcinoma [88], and is necessary for the inva-
sion of lung cancer [89]. These facts suggest that DGK can
be a target of multiple diseases including diabetes, cancer,
and neuronal diseases. Again, in addition to the compre-
hensive research to reveal subtype-specific functions DGKs,
subtype-specific compounds would be necessary to develop
drugs targeting DGKs without side effect.
Conclusion
In conclusion, some DGKs are involved in formation and
maintenance of spines through the control of membrane
lipid and protein-protein interactions, contributing higher
brain functions including memory and emotion (Figure 2).
Thus, some DGKs can be therapeutic target for neuronal
diseases including mood disorder, memory loss, and seizure.
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